Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep785 | Endocrine tumours and neoplasia | ECE2017

ER status heterogeneity in breast cancer: role in response to endocrine treatment

Gagliano Teresa , Ditsiou Angeliki , Grothey Arnhild , Giamas Georgios

Tumor heterogeneity affects diagnosis, prognosis and response to therapy. Heterogeneity is found in both normal and neoplastic human mammary gland. For example, luminal estrogen receptor (ER)-negative cells can give rise to various phenotypes, including ER-negative and ER-positive mammary tumors, suggesting that the cell-of-origin does not necessarily reflect the tumor type. Regarding ER status, heterogeneity can challenge endocrine therapies; elimination of responsive clones ...

ea0056p654 | Endocrine tumours and neoplasia | ECE2018

Fibroblast-kinome silencing to identifies putative mediator of Triple-negative breast cancer (TNBC) invasion

Gagliano Teresa , Vella Viviana , Bienkowska Kamila , Ditsiou Angeliki , Giamas Georgios

Kinases represent a main therapeutic targets in cancer treatment as their impairing is related to tumor growth and progression. Despite the increasing evidence that tumor microenvironment (TME) signaling influences the behavior of surrounding cancer epithelial cells, still little is known about what changes in stromal cells influence tumor cells’ behavior. TNBC patients are still lacking an effective therapy, as not much is known about the biology of this BC tumor subtype...

ea0063p38 | Adrenal and Neuroendocrine Tumours 1 | ECE2019

Influence of Tumor Microenviroment in response modulation to treatment in human BP-NENs

Bresciani Giulia , Ditsiou Angeliki , Cilibrasi Chiara , Vella Viviana , Giamas Georgios , Zatelli Maria Chiara , Gagliano Teresa

Introduction: Broncho-Pulmonary Neoplasms (BP-NENs) are rare neoplasms arising from neuroendocrine cells of the respiratory epithelium. Since previous studies in our lab have demonstrated the efficacy ofEverolimus, approved for BP-NENs treatment, and Dinaciclib, a Cyclins and CdKs inhibitor, on monolayer system we have investigated if a more complex tumour system could generate a change in drugs effects and cell resistance. Therefore, through the use of 3D culture model, we ha...

ea0056p651 | Endocrine tumours and neoplasia | ECE2018

Targeting Treatment Resistance in Breast Cancer Subtypes via LMTK3 Inhibition

Ditsiou Angeliki , Gagliano Teresa , Prodromou Chrisostomos , Gascon Jose , Mumford Sophie , Grand Darren Le , Giamas Georgios

Introduction: LMTK3 is an oncogenic Receptor Tyrosine Kinase (RTK) implicated in resistance to endocrine therapy in breast cancer. Initially, LMTK3 was described as a regulator of Estrogen Receptor alpha (ERα) since it was found able to protect it from ubiquitin-mediated proteasomal degradation. In a cohort of breast cancer (BC) patients (n>600), LMTK3 protein levels and intronic polymorphisms were significantly associated with disease-free and overall surviv...

ea0063p464 | Adrenal and Neuroendocrine Tumours 2 | ECE2019

EGFR and IGF1R affect Sunitinib activity: novel targets for Broncho-Pulmonary Neuroendocrine Neoplasm treatment

Bresciani Giulia , Ditsiou Angeliki , Cilibrasi Chiara , Vella Viviana , Rea Federico , Schiavon Marco , Cavallesco Narciso Giorgio , Giamas Georgios , Zatelli Maria Chiara , Gagliano Teresa

Background: Available medical treatments for Broncho-Pulmonary Neuroendocrine Neoplasm (BP-NENs) derived from clinical trials are not specific for the management of this malignancy. Sunitinib, a multi-receptor tyrosine-kinases (RTKs) inhibitor, mainly described as VEGFR inhibitor, has shown its efficacy in Pancreatic NENs but there are not available data about its action in BP-NENs. Our aim was to understand the effects of RTKs inhibition promoted by Sunitinib in order to eval...